Yomna E. Dean, Jose J. Loayza Pintado, Samah S. Rouzan, Lucy L. Nale, Ahmed Abbas, Abdulla Aboushaira, Farah Alkasajy, Ahmed A. Ghanem, Vinayak Mahesh Patil, Yana Gordeyeva, Karam R. Motawea, Masako Lien Petty Le, Adham Galal, Laura Cicani, Raneem Attta, Ahmed Soliman, Lamya Alzabidi, Anuj Subedi, Nikhat Anjum, Abdullah Nahedh, Tamer Mady, Yusef Hazimeh, Hossam Amin, Hani Aiash
{"title":"The Relationship Between Irritable Bowel Syndrome and Metabolic Syndrome: A Systematic Review and Meta-Analysis of 49,662 Individuals","authors":"Yomna E. Dean, Jose J. Loayza Pintado, Samah S. Rouzan, Lucy L. Nale, Ahmed Abbas, Abdulla Aboushaira, Farah Alkasajy, Ahmed A. Ghanem, Vinayak Mahesh Patil, Yana Gordeyeva, Karam R. Motawea, Masako Lien Petty Le, Adham Galal, Laura Cicani, Raneem Attta, Ahmed Soliman, Lamya Alzabidi, Anuj Subedi, Nikhat Anjum, Abdullah Nahedh, Tamer Mady, Yusef Hazimeh, Hossam Amin, Hani Aiash","doi":"10.1002/edm2.70041","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Studies have shown mixed results regarding the association between irritable bowel syndrome (IBS) and metabolic syndrome (MS); This study aimed to assess the susceptibility of IBS patients to MS and its individual components.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>PubMed, Scopus, Embase, and Web of Science were searched on 1/1/2023. Eligible studies were screened, and data on study characteristics, IBS diagnostic criteria, and metabolic syndrome components were extracted. Data were analysed in RevMan 5.4, with results reported as relative risk (RR) or mean difference (MD) and 95% confidence intervals. Statistical significance was set at <i>p</i> < 0.05.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>IBS was associated with an increased risk of MS (RR = 2.05, 95% CI = 1.50–2.79, <i>p</i> < 0.00001), with a higher risk among IBS-D patients (RR = 3.09, 95% CI = 2.41–3.97, <i>p</i> < 0.00001). IBS patients showed increased HOMA-IR (MD = 0.21, 95% CI = 0.15–0.26, <i>p</i> < 0.00001), higher obesity risk (RR = 1.46, 95% CI = 1.10–1.93, <i>p</i> = 0.009), elevated BMI (MD = 1.51, 95% CI = 0.98–2.03, <i>p</i>-value < 0.00001), waist circumference (MD = 5.01, 95% CI = 1.29–8.72, <i>p</i> = 0.008), and an association with systolic hypertension (MD = −0.50, 95% CI = −0.60 to −0.40, <i>p</i>-value < 0.00001). IBS was also linked to higher LDL (MD = 5.98, 95% CI = 0.91–11.05, <i>p</i> = 0.02), total cholesterol (MD = 12.21, 95% CI = 6.23–18.18, <i>p</i> < 0.0001), and triglycerides (MD = 11.93, 95% CI = 11.55–12.31, <i>p</i> < 0.00001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This analysis indicates a potential association between IBS and metabolic syndrome, including its components such as obesity, hypertension, and lipid profile abnormalities. However, significant heterogeneity among studies limits the generalisability of these findings. Clinicians should remain aware of the possible link and consider individualised preventive and management strategies.</p>\n </section>\n </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70041","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology, Diabetes and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/edm2.70041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Studies have shown mixed results regarding the association between irritable bowel syndrome (IBS) and metabolic syndrome (MS); This study aimed to assess the susceptibility of IBS patients to MS and its individual components.
Methods
PubMed, Scopus, Embase, and Web of Science were searched on 1/1/2023. Eligible studies were screened, and data on study characteristics, IBS diagnostic criteria, and metabolic syndrome components were extracted. Data were analysed in RevMan 5.4, with results reported as relative risk (RR) or mean difference (MD) and 95% confidence intervals. Statistical significance was set at p < 0.05.
Results
IBS was associated with an increased risk of MS (RR = 2.05, 95% CI = 1.50–2.79, p < 0.00001), with a higher risk among IBS-D patients (RR = 3.09, 95% CI = 2.41–3.97, p < 0.00001). IBS patients showed increased HOMA-IR (MD = 0.21, 95% CI = 0.15–0.26, p < 0.00001), higher obesity risk (RR = 1.46, 95% CI = 1.10–1.93, p = 0.009), elevated BMI (MD = 1.51, 95% CI = 0.98–2.03, p-value < 0.00001), waist circumference (MD = 5.01, 95% CI = 1.29–8.72, p = 0.008), and an association with systolic hypertension (MD = −0.50, 95% CI = −0.60 to −0.40, p-value < 0.00001). IBS was also linked to higher LDL (MD = 5.98, 95% CI = 0.91–11.05, p = 0.02), total cholesterol (MD = 12.21, 95% CI = 6.23–18.18, p < 0.0001), and triglycerides (MD = 11.93, 95% CI = 11.55–12.31, p < 0.00001).
Conclusions
This analysis indicates a potential association between IBS and metabolic syndrome, including its components such as obesity, hypertension, and lipid profile abnormalities. However, significant heterogeneity among studies limits the generalisability of these findings. Clinicians should remain aware of the possible link and consider individualised preventive and management strategies.
背景:关于肠易激综合征(IBS)和代谢综合征(MS)之间的关系,研究显示了不同的结果;本研究旨在评估肠易激综合征患者对多发性硬化症及其个别成分的易感性。方法于2023年1月1日检索PubMed、Scopus、Embase和Web of Science。筛选符合条件的研究,提取有关研究特征、肠易激综合征诊断标准和代谢综合征成分的数据。数据在RevMan 5.4中进行分析,结果以相对危险度(RR)或平均差(MD)和95%置信区间报告。p <; 0.05为统计学意义。结果IBS与MS风险增加相关(RR = 2.05, 95% CI = 1.50-2.79, p < 0.00001), IBS- d患者的风险更高(RR = 3.09, 95% CI = 2.41-3.97, p < 0.00001)。肠易激综合征患者HOMA-IR升高(MD = 0.21, 95% CI = 0.15-0.26, p < 0.00001),肥胖风险增高(RR = 1.46, 95% CI = 1.10-1.93, p = 0.009), BMI升高(MD = 1.51, 95% CI = 0.98-2.03, p = 0.00001),腰围(MD = 5.01, 95% CI = 1.29-8.72, p = 0.008),并与收缩期高血压相关(MD = - 0.50, 95% CI = - 0.60 - - 0.40, p = 0.00001)。IBS还与较高的LDL (MD = 5.98, 95% CI = 0.91-11.05, p = 0.02)、总胆固醇(MD = 12.21, 95% CI = 6.23-18.18, p < 0.0001)和甘油三酯(MD = 11.93, 95% CI = 11.55-12.31, p < 0.00001)有关。结论:该分析表明肠易激综合征与代谢综合征之间存在潜在关联,包括其组成部分,如肥胖、高血压和血脂异常。然而,研究之间的显著异质性限制了这些发现的普遍性。临床医生应该继续意识到可能的联系,并考虑个性化的预防和管理策略。